The U.S. government has announced its latest selections for Medicare price negotiations, targeting 15 drugs set for discussions in 2028. This list notably features Gilead Sciences’ prominent HIV treatment, Biktarvy, alongside Pfizer’s arthritis medication, Xeljanz.
Background on the Negotiation Process
This marks the third round of negotiations under the Inflation Reduction Act of 2022, a significant legislative move initiated during Joe Biden’s presidency. The Act empowers the government to engage in price negotiations for certain medications acquired through the Medicare program, which serves individuals aged 65 and older, as well as those with disabilities.
Despite facing staunch opposition from the pharmaceutical industry and numerous unsuccessful legal challenges, the initial round of negotiated prices for 10 drugs took effect earlier this year, showcasing the government’s commitment to this new pricing strategy.
A Diverse List of Medications
The 2028 negotiation list is not limited to oral medications; it also includes treatments administered in healthcare settings. Noteworthy inclusions are Novartis’ psoriasis drug, Cosentyx, and AbbVie’s widely recognized Botox. The list extends to Eli Lilly’s diabetes medication, Trulicity, further illustrating the range of therapies under scrutiny.
Anticipating Market Reactions
Market analysts, such as Evan Seigerman from BMO Capital Markets, suggest that the previous rounds of negotiations have shown reasonable outcomes. With many of these medicines nearing the end of their exclusivity periods, the anticipated impacts on the pharmaceutical market appear manageable.
The Centers for Medicare and Medicaid Services (CMS) previously indicated that the negotiated prices for 15 drugs set to begin in 2027 would yield substantial savings, projected at 36% compared to current spending levels, equating to approximately $8.5 billion in savings.
Gilead’s Position in the Market
Gilead’s Biktarvy, which generated $13.4 billion in sales in 2024, had been widely expected to feature on the negotiation list. The company recently announced agreements with three generic manufacturers, extending its U.S. patent protection until April 2036. However, analysts from JP Morgan predict that only a small fraction—around 20% of U.S. sales—will be affected by the upcoming negotiations.
Financial Implications for Drugmakers
Following the announcement of the negotiation list, shares of several pharmaceutical giants, including Gilead, Lilly, AbbVie, Johnson & Johnson, and Pfizer, experienced a modest increase of nearly 2% in after-hours trading. This reaction suggests a level of investor confidence amidst the ongoing changes in drug pricing policies.
Ongoing Legal Challenges
The pharmaceutical industry continues to push back against the Inflation Reduction Act in the courts, arguing that government-imposed price setting is detrimental to American patients. Elizabeth Carpenter, a key figure at the trade group PhRMA, voiced concerns that since the law’s implementation, seniors have faced increased costs, reduced options, and heightened barriers to accessing care.
Value Proposition of Selected Drugs
Representatives from Novartis defended their products, Cosentyx and Kisqali, emphasizing the significant value they provide to patients. They argue that the negotiation framework introduced by the government could have enduring implications for patient care and access to vital medications.
Conclusion: A Pivotal Moment in Drug Pricing
As the Medicare price negotiations move forward, the stakes are high for both patients and pharmaceutical companies. The outcome could reshape the landscape of drug pricing in the United States, potentially leading to lower costs for consumers while challenging the revenue models of major drug manufacturers. The coming years will reveal whether this initiative can strike a balance between affordability and innovation in healthcare.
- Key drugs selected for negotiation include Biktarvy and Xeljanz.
- The negotiations aim to reduce Medicare spending significantly.
- Pharmaceutical companies are actively contesting the legislation.
- Market analysts remain cautiously optimistic about the impacts.
- The negotiations may alter the availability of certain medications.
Read more → www.cnbc.com